Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Pulmonology

The Standard of Care: Managing and Slowing IPF

At a Glance

While there is no cure for Idiopathic Pulmonary Fibrosis (IPF), modern treatments can slow its progression by roughly 50%. The standard of care includes antifibrotic medications like nintedanib and pirfenidone, pulmonary rehabilitation, supplemental oxygen, and managing acid reflux.

While there is currently no cure for Idiopathic Pulmonary Fibrosis (IPF), the “standard of care” has evolved significantly. The goal of modern treatment is to slow the progression of the disease, manage your symptoms, and improve your daily quality of life [1].

Antifibrotic Medications

The cornerstone of IPF treatment involves two medications known as antifibrotics: nintedanib (Ofev) and pirfenidone (Esbriet) [2][3]. It is important to understand that these drugs do not reverse existing scars, but they are clinically proven to slow the decline of your Forced Vital Capacity (FVC)—a measure of how much air your lungs can hold—by roughly 50% [4][5].

Medication Common Side Effects Management Tips
Nintedanib Diarrhea, nausea, vomiting, and liver enzyme elevations. Must be taken with food to improve how your body tolerates it. Diarrhea can be severe, but doctors can prescribe anti-diarrheal medications (like loperamide) or adjust your dosage to keep it manageable [6].
Pirfenidone Nausea, rash, abdominal pain, and light sensitivity (photosensitivity). Must be taken with food. Use sunscreen and protective clothing daily.

Both medications require regular blood tests to monitor your liver function, as they can occasionally cause liver enzyme elevations [7].

Supplemental Oxygen

As IPF progresses, your lungs may struggle to keep enough oxygen in your blood. Doctors often use a 6-minute walk test to see if your oxygen levels drop during activity [8].

  • When it’s needed: Supplemental oxygen is typically considered if your oxygen saturation (SpO2) falls to 88% or below (<=88%) [9].
  • The benefit: While it doesn’t treat the scarring itself, supplemental oxygen can reduce shortness of breath and help you stay active [8].

Pulmonary Rehabilitation

Pulmonary rehabilitation is a specialized program of exercise and education designed for people with chronic lung diseases [10].

  • Exercise Capacity: It helps you improve your physical endurance and muscle strength, which can make daily tasks easier [11].
  • Quality of Life: Patients often report feeling more in control of their condition and experiencing less anxiety and fatigue after completing a program [12][13].

Lung Transplantation

For some patients, a lung transplant may be an option. Because IPF can be unpredictable, early referral to a transplant center for a “baseline” evaluation is often recommended [14][15].

  • Referral Criteria: Doctors look at factors like your FVC decline, your GAP index (a risk score based on Gender, Age, and Physiology), and whether you need supplemental oxygen [16][17].
  • Transplant Reality: However, transplant centers have strict age cutoffs (often around 65-70 years old) and require you to be free of other major physical comorbidities to qualify for this intensive surgery [18].
  • Timing: Referral is not the same as surgery; it is a way to ensure you are “in the system” early if you qualify and if the disease progresses more quickly than expected [19].

Additional Support

Standard care also includes staying up-to-date on vaccinations (such as flu, pneumonia, and COVID-19) and managing Gastroesophageal Reflux Disease (GERD) [20][21]. Microaspiration—small amounts of stomach acid entering the lungs—is thought to potentially worsen scarring, so managing reflux is a common part of the treatment plan [22][23].

Common questions in this guide

Which antifibrotic medication is right for me?
The choice between nintedanib and pirfenidone depends on your specific health factors and tolerance for potential side effects. Both medications are clinically proven to slow the decline of lung function by roughly 50 percent.
When do I need to start using supplemental oxygen for IPF?
Doctors typically recommend supplemental oxygen when your oxygen saturation falls to 88 percent or below. While it does not treat the lung scarring itself, it helps reduce shortness of breath and allows you to stay active.
What are the side effects of IPF medications?
Nintedanib commonly causes diarrhea and nausea, while pirfenidone can cause nausea, skin rash, and sensitivity to sunlight. Both medications require regular blood tests to monitor your liver function, and both should be taken with food.
Why do I need to manage acid reflux with IPF?
Small amounts of stomach acid from acid reflux can enter the lungs, a process called microaspiration. This acid may worsen lung scarring, making the management of gastroesophageal reflux disease an important part of your overall treatment plan.
When should I be evaluated for a lung transplant?
Because IPF can be unpredictable, an early referral for a baseline lung transplant evaluation is often recommended. This ensures you are in the system early if you qualify, though strict age and general health criteria apply for the surgery.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current lung function (FVC), which antifibrotic—nintedanib or pirfenidone—is the better fit for me?
  2. 2.What is your plan for monitoring my liver function once I start an antifibrotic medication?
  3. 3.At what oxygen saturation (SpO2) level should I start using supplemental oxygen at home or while exercising?
  4. 4.Can you refer me to a pulmonary rehabilitation program that has experience with IPF patients?
  5. 5.Should we consider a referral for a baseline lung transplant evaluation now, given the progressive nature of IPF?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Idiopathic Pulmonary Fibrosis.

    Lederer DJ, Martinez FJ

    The New England journal of medicine 2018; (378(19)):1811-1823 doi:10.1056/NEJMra1705751.

    PMID: 29742380
  2. 2

    Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.

    Dempsey TM, Sangaralingham LR, Yao X, et al.

    American journal of respiratory and critical care medicine 2019; (200(2)):168-174 doi:10.1164/rccm.201902-0456OC.

    PMID: 31150266
  3. 3

    Interstitial Lung Disease: A Review.

    Maher TM

    JAMA 2024; (331(19)):1655-1665 doi:10.1001/jama.2024.3669.

    PMID: 38648021
  4. 4

    Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.

    Hoffmann-Vold AM, Weigt SS, Saggar R, et al.

    EBioMedicine 2019; (50()):379-386 doi:10.1016/j.ebiom.2019.10.050.

    PMID: 31732480
  5. 5

    Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis.

    Mei Q, Liu Z, Zuo H, et al.

    Frontiers in pharmacology 2021; (12()):797292 doi:10.3389/fphar.2021.797292.

    PMID: 35126134
  6. 6

    Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

    Distler O, Highland KB, Gahlemann M, et al.

    The New England journal of medicine 2019; (380(26)):2518-2528 doi:10.1056/NEJMoa1903076.

    PMID: 31112379
  7. 7

    Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study.

    Aycicek O, Keskin S, Haciosmanoglu M, et al.

    Medicina (Kaunas, Lithuania) 2025; (61(2)) doi:10.3390/medicina61020283.

    PMID: 40005400
  8. 8

    Factors affecting dyspnea after the 6-minute walk test in idiopathic pulmonary fibrosis patients presenting with exercise-induced hypoxemia.

    Morino A, Takahashi H, Chiba H, Ishiai S

    Journal of physical therapy science 2017; (29(8)):1458-1462 doi:10.1589/jpts.29.1458.

    PMID: 28878483
  9. 9

    Twenty-four-hour ambulatory oximetry monitoring in a patient with idiopathic pulmonary fibrosis for assisting in the discharge instruction on activities of daily living: a case report.

    Sekikawa K, Aizawa F, Sekikawa N, et al.

    Journal of physical therapy science 2020; (32(11)):768-771 doi:10.1589/jpts.32.768.

    PMID: 33281294
  10. 10

    Clinical evidence for improving exercise tolerance and quality of life with pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

    Lei S, Li X, Xie Y, Li J

    Clinical rehabilitation 2022; (36(8)):999-1015 doi:10.1177/02692155221095481.

    PMID: 35481421
  11. 11

    Impact of Pulmonary Rehabilitation on Exercise Tolerance and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A SYSTEMATIC REVIEW AND META-ANALYSIS.

    Gomes-Neto M, Silva CM, Ezequiel D, et al.

    Journal of cardiopulmonary rehabilitation and prevention 2018; (38(5)):273-278 doi:10.1097/HCR.0000000000000273.

    PMID: 29351129
  12. 12

    Exercise and Chronic Obstructive Pulmonary Disease (COPD).

    Fiorentino G, Esquinas AM, Annunziata A

    Advances in experimental medicine and biology 2020; (1228()):355-368 doi:10.1007/978-981-15-1792-1_24.

    PMID: 32342470
  13. 13

    Mood disorder in idiopathic pulmonary fibrosis: response to pulmonary rehabilitation.

    Edwards GD, Polgar O, Patel S, et al.

    ERJ open research 2023; (9(3)) doi:10.1183/23120541.00585-2022.

    PMID: 37228278
  14. 14

    [Selection of lung transplant candidates in France in 2019].

    Falque L, Gheerbrant H, Saint-Raymond C, et al.

    Revue des maladies respiratoires 2019; (36(4)):508-518 doi:10.1016/j.rmr.2018.03.009.

    PMID: 31006579
  15. 15

    [Indications for Lung Transplantation - Updates Since the Last ISHLT Recommendations].

    Kovacs Z, Benazzo A, Jaksch P

    Zentralblatt fur Chirurgie 2025; (150(3)):256-260 doi:10.1055/a-2563-3691.

    PMID: 40373816
  16. 16

    Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis.

    Oldham JM, Neely ML, Wojdyla DM, et al.

    Chest 2025; (168(2)):415-422 doi:10.1016/j.chest.2025.02.018.

    PMID: 40020995
  17. 17

    The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone.

    Harari S, Caminati A, Confalonieri M, et al.

    The clinical respiratory journal 2019; (13(3)):166-173 doi:10.1111/crj.12999.

    PMID: 30675755
  18. 18

    Idiopathic Pulmonary Fibrosis: Treatment and Prognosis.

    Fujimoto H, Kobayashi T, Azuma A

    Clinical medicine insights. Circulatory, respiratory and pulmonary medicine 2015; (9(Suppl 1)):179-185 doi:10.4137/CCRPM.S23321.

    PMID: 27980445
  19. 19

    Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible.

    Balestro E, Cocconcelli E, Tinè M, et al.

    Medicina (Kaunas, Lithuania) 2019; (55(10)) doi:10.3390/medicina55100702.

    PMID: 31635104
  20. 20

    Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases.

    Chiner-Vives E, Cordovilla-Pérez R, de la Rosa-Carrillo D, et al.

    Archivos de bronconeumologia 2022; (58 Suppl 1()):39-50 doi:10.1016/j.arbres.2022.03.011.

    PMID: 35501222
  21. 21

    The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study.

    Reynolds CJ, Del Greco M F, Allen RJ, et al.

    The European respiratory journal 2023; (61(5)) doi:10.1183/13993003.01585-2022.

    PMID: 37080571
  22. 22

    Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix.

    Wu X, Xiao X, Fang H, et al.

    Frontiers in pharmacology 2024; (15()):1348708 doi:10.3389/fphar.2024.1348708.

    PMID: 38414734
  23. 23

    Mediators of the association between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis.

    Tao H, Dong Y, Chen X, Peng L

    The European respiratory journal 2023; (62(6)) doi:10.1183/13993003.00323-2023.

    PMID: 37857422

This page explains the standard treatments for idiopathic pulmonary fibrosis for educational purposes only. Always consult your pulmonologist to determine the safest and most effective treatment plan for your specific condition.

Get notified when new evidence is published on Idiopathic pulmonary fibrosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.